SCHEMBL5336908

SCHEMBL5336908

COc1ccc(NC(=O)Nc2ccc(-c3cccc4noc(Nc5ccccc5)c34)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 8/20 0.59
▸ KIT P10721 6/20 0.59
▸ FLT3 P36888 5/20 0.52
▸ TP53 P04637 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ POLB P06746 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ CSF1R P07333 2/20 0.45
▸ IGF1R P08069 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ TEK Q02763 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ AURKA O14965 1/20 0.44
▸ ROCK2 O75116 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1381023 0.83 KDR (0.70) KDRKITFLT3SMN1; SMN2POLB
SCHEMBL5362753 0.81 KDR (0.55) KDRKITFLT3CSF1RMEN1
SCHEMBL4740220 0.78 KDR (0.72) KDRKITFLT3TP53TSHR
SCHEMBL1383101 0.77 KDR (0.67) KDRKITFLT3CSF1RAURKA
SCHEMBL1347812 0.74 KIT (1.00) KDRKITFLT3CSF1RAURKA
SCHEMBL5333922 0.73 KDR (0.51) KDRKITFLT3SMN1; SMN2KDM4E
SCHEMBL11106394 0.73 RAB9A (0.85) TP53TSHRSMN1; SMN2KDM4EPOLB
SCHEMBL4737316 0.70 KDR (0.68) KDRKITFLT3CSF1RLCK
SCHEMBL1379463 0.70 KDR (0.71) KDRKITFLT3CSF1RNPC1
SCHEMBL1383479 0.69 KDR (0.70) KDRKITFLT3CSF1RAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 — — EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 — — WO claimed
Send feedback